Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as IMOVAX Polio ™
Poliomyelitis Vaccine inactivated · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | - |
| Group 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Poliomyelitis Vaccine inactivated | BIOLOGICAL | 0.5 mL, Intramuscular |
| Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell) | BIOLOGICAL | 1g dragee, oral |
Inclusion Criteria: * Aged 2 months (60-70 days) on the day of inclusion into the study * Born at full term pregnancy ( over 36 weeks) with a birth weight ≥ 2.5 kg 2Ibs) or more * Parent(s) or legal representative able to understand and give authorization and sign informed consent for participation...
Poliomyelitis Vaccine inactivated is used to prevent poliomyelitis, commonly called polio, an infectious disease caused by poliovirus. It is an inactivated, injectable vaccine, meaning it contains killed virus rather than live virus. Sanofi develops this vaccine, which is studied in infants and other populations for protection against polio infection.
Sanofi, which trades under the ticker SNY, is the developer of Poliomyelitis Vaccine inactivated. Sanofi is a global pharmaceutical company with an established vaccines business. The company conducted clinical development of this inactivated polio vaccine, including a Phase 3 study in Chinese infants.
Poliomyelitis Vaccine inactivated has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was an active-controlled, randomized Phase 3 trial that enrolled 600 participants. The vaccine is an investigational product in the context of this clinical program.
Poliomyelitis Vaccine inactivated was evaluated in the Phase 3 trial NCT00348387, titled Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV. The trial enrolled 600 infants in China, was randomized and active-controlled, and has been completed. Participants were at least 60 days old, and the study included healthy volunteers.
Yes, Imovax Polio is the brand name associated with Poliomyelitis Vaccine inactivated. The Phase 3 trial NCT00348387 refers to the product as Imovax Polio while comparing it to local oral polio vaccine in Chinese infants. Readers searching for Imovax Polio are looking at the same inactivated polio vaccine developed by Sanofi.
Poliomyelitis Vaccine inactivated works as a vaccine against poliomyelitis. It is an inactivated vaccine, meaning it uses killed poliovirus to stimulate an immune response without causing polio disease. The Phase 3 trial NCT00348387 assessed immunogenicity and safety in Chinese infants, comparing the inactivated vaccine with local oral polio vaccine.